Document is current

Article History

Received: 18 October 2023

Accepted: 27 March 2024

First Online: 5 April 2024

Declarations

:

: Bone marrow samples were obtained after approval by the Ethics Committee on Human Experimentation of the Medical Faculty of Heidelberg University (S-117/2014 ‘Molekulare Charakterisierung hypertropher Differenzierungswege und ihre Vermeidung bei der in vitro Chondrogenese humaner mesenchymaler Stammzellen’ approved in May 2014, S-845/2019 ‘Gezielte Steuerung hypertropher Differenzierungswege zur Verbesserung der in vitro Chondrogenese humaner mesenchymaler Stammzellen’ approved in December 2019) and in agreement with the Helsinki Declaration of 1975 in its latest version.

: All animal experiments were approved by the local animal experimentation committee (G-210/18) and carried out in accordance with European Laboratory Animal Science guidelines.

: Not Applicable.

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The BMP-ALK2/3-inhibitor compound A was obtained from Novartis Pharma AG, Basel, from where it can be provided upon request under a material transfer agreement specifying nondisclosure conditions, and restrictions regarding the use of the materials and the results obtained therewith.